Back to Search
Start Over
Diverse underlying proliferation response to growth factors in imatinib-treated Philadelphia chromosome-positive leukemias.
- Source :
-
Leukemia research [Leuk Res] 2013 Jan; Vol. 37 (1), pp. 93-101. Date of Electronic Publication: 2012 Oct 23. - Publication Year :
- 2013
-
Abstract
- Since BCR-ABL plays an essential role in the growth factor-independent proliferation of Philadelphia chromosome (Ph)+ leukemia cells, imatinib treatment of Ph+ leukemia cells inactivates signaling pathways of BCR-ABL, and subsequent addition of growth factors (GFs) could restore the signaling pathways without reactivating BCR-ABL. Here we demonstrated that non-lymphoid Ph+ leukemia cell lines responded to diverse GFs depending on their immunophenotype and gene expression of transcription factors and GF receptors, while lymphoid Ph+ leukemia cell lines restrictively responded to flit3 ligand and interleukin-7, suggesting that GF sensitivity of imatinib-treated Ph+ leukemia cells could be powerful for specifying their distinctive lineage.<br /> (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Subjects :
- Benzamides
Cell Line, Tumor
Cell Proliferation drug effects
Granulocyte Colony-Stimulating Factor pharmacology
Granulocyte-Macrophage Colony-Stimulating Factor pharmacology
Humans
Imatinib Mesylate
Interleukin-6 pharmacology
Leukemia genetics
Leukemia pathology
Antineoplastic Agents pharmacology
Intercellular Signaling Peptides and Proteins pharmacology
Leukemia drug therapy
Philadelphia Chromosome
Piperazines pharmacology
Pyrimidines pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1873-5835
- Volume :
- 37
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Leukemia research
- Publication Type :
- Academic Journal
- Accession number :
- 23099235
- Full Text :
- https://doi.org/10.1016/j.leukres.2012.10.001